TLC
Income statement / Annual
Last year (2020), Taiwan Liposome Company, Ltd.'s total revenue was $101.93 M,
a decrease of 51.26% from the previous year.
In 2020, Taiwan Liposome Company, Ltd.'s net income was -$983.31 M.
See Taiwan Liposome Company, Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
| Operating Revenue |
$101.93 M
|
$209.14 M
|
$62.32 M
|
$49.64 M
|
$41.67 M
|
$59.77 M
|
$95.92 M
|
$158.64 M
|
$240.66 M
|
$78.23 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$101.93 M |
$209.14 M |
$62.32 M |
$49.64 M |
$41.67 M |
$59.77 M |
$95.92 M |
$158.64 M |
$240.66 M |
$78.23 M |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$967.50 M
|
$860.42 M
|
$832.58 M
|
$813.25 M
|
$736.88 M
|
$634.85 M
|
$664.45 M
|
$470.24 M
|
$374.58 M
|
$257.33 M
|
| General & Administrative
Expenses |
$145.77 M
|
$166.38 M
|
$147.74 M
|
$134.87 M
|
$141.49 M
|
$138.32 M
|
$102.99 M
|
$98.14 M
|
$55.85 M
|
$46.03 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$145.77 M
|
$166.38 M
|
$147.74 M
|
$134.87 M
|
$141.49 M
|
$138.32 M
|
$102.99 M
|
$98.14 M
|
$55.85 M
|
$46.03 M
|
| Other Expenses |
-$28.23 M |
-$16.05 M |
-$26.23 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$1.09 B |
$1.01 B |
$954.09 M |
$948.12 M |
$878.37 M |
$773.17 M |
$767.43 M |
$568.38 M |
$430.44 M |
$303.36 M |
| Cost And Expenses |
$1.09 B |
$1.01 B |
$954.09 M |
$948.12 M |
$878.37 M |
$773.17 M |
$767.43 M |
$568.38 M |
$430.44 M |
$303.36 M |
| Interest Income |
$1.19 M |
$7.40 M |
$2.45 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$472,000.00 |
$311,000.00 |
| Interest Expense |
$16.35 M |
$23.66 M |
$9.89 M |
$3.39 M |
$2.94 M |
$2.59 M |
$1.31 M |
$1.63 M |
$2.14 M |
$2.39 M |
| Depreciation &
Amortization |
$56.17 M
|
$71.40 M
|
$47.46 M
|
$52.50 M
|
$75.24 M
|
$60.93 M
|
$51.51 M
|
$30.18 M
|
$25.73 M
|
$23.12 M
|
| EBITDA |
-$909.66 M
|
-$708.34 M
|
-$843.36 M
|
-$817.13 M
|
-$745.57 M
|
-$611.72 M
|
-$579.75 M
|
-$368.80 M
|
-$159.01 M
|
-$191.08 M
|
| EBITDA Ratio |
-8.92 |
-3.39 |
-13.53 |
-16.46 |
-17.89 |
-10.23 |
-6.04 |
-2.32 |
-0.66 |
-2.44 |
| Operating Income Ratio
|
-9.65
|
-3.83
|
-14.31
|
-18.1
|
-20.08
|
-11.94
|
-7
|
-2.58
|
-0.79
|
-2.88
|
| Total Other
Income/Expenses Net |
$933,000.00
|
-$1.80 M
|
-$8.94 M
|
$25.48 M
|
$12.95 M
|
$38.16 M
|
$38.94 M
|
$9.12 M
|
$2.90 M
|
$8.54 M
|
| Income Before Tax |
-$982.18 M |
-$803.40 M |
-$900.71 M |
-$873.01 M |
-$823.75 M |
-$675.24 M |
-$632.57 M |
-$400.61 M |
-$186.88 M |
-$216.59 M |
| Income Before Tax Ratio
|
-9.64
|
-3.84
|
-14.45
|
-17.59
|
-19.77
|
-11.3
|
-6.59
|
-2.53
|
-0.78
|
-2.77
|
| Income Tax Expense |
$1.13 M |
$4.12 M |
$867,000.00 |
$951,000.00 |
$563,000.00 |
$450,000.00 |
$292,000.00 |
$359,000.00 |
$251,000.00 |
$394,000.00 |
| Net Income |
-$983.31 M |
-$807.52 M |
-$901.57 M |
-$873.96 M |
-$824.32 M |
-$675.69 M |
-$632.86 M |
-$400.97 M |
-$187.13 M |
-$216.99 M |
| Net Income Ratio |
-9.65 |
-3.86 |
-14.47 |
-17.61 |
-19.78 |
-11.3 |
-6.6 |
-2.53 |
-0.78 |
-2.77 |
| EPS |
-24.89 |
-24.64 |
-28.75 |
-31.5 |
-29.78 |
-24.5 |
-23.08 |
-16.44 |
-9.5 |
-14.6 |
| EPS Diluted |
-24.89 |
-24.64 |
-28.75 |
-31.5 |
-29.78 |
-24.5 |
-23.08 |
-16.44 |
-9.5 |
-14.6 |
| Weighted Average Shares
Out |
$39.51 M
|
$32.77 M
|
$31.36 M
|
$27.74 M
|
$27.68 M
|
$27.58 M
|
$27.42 M
|
$24.39 M
|
$19.70 M
|
$14.86 M
|
| Weighted Average Shares
Out Diluted |
$39.51 M
|
$32.77 M
|
$31.36 M
|
$27.74 M
|
$27.68 M
|
$27.58 M
|
$27.42 M
|
$24.39 M
|
$19.70 M
|
$14.86 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
